SCHEDULE: Armistice Capital Discloses 4.99% Stake in PDS Biotech
Beneficial Ownership Report (Schedule 13G Amendment)
Armistice Capital, LLC and Steven Boyd report a 4.99% passive beneficial ownership stake in PDS Biotechnology Corp.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in PDS Biotechnology Corp.
- As of June 30, 2025, the Reporting Persons beneficially own an aggregate of 2,283,288 shares of PDS Biotechnology Corp.'s Common Stock.
- This ownership represents 4.99% of the total outstanding shares of the class.
- Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- The Reporting Persons hold shared voting power and shared dispositive power over all 2,283,288 shares, with no sole voting or dispositive power.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as the filing is a standard beneficial ownership report indicating a passive investment just below the 5% threshold, with no operational or financial performance details.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of passive beneficial ownership by an investment firm in a biotechnology company. It does not provide specific insights into broader industry trends or competitive dynamics beyond the fact that an investment firm sees value in holding a stake in PDS Biotechnology Corp.
Stakeholder Impact
- Minimal direct impact on shareholders, employees, customers, suppliers, or creditors as this is a passive investment disclosure and does not indicate any intent to influence control or operations.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (beneficial ownership threshold). |
| 08/14/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
PDS Biotechnology Corp, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.